GlassScriptPhysician profile
Nichol Raulerson
NPI 1053491753
$5,385.96
in general payments reported to CMS, 2019-2025
24 companies · $1,425 in 2025
The $1,425 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $802 · 2022: $770 · 2023: $1,049 · 2024: $1,340 · 2025: $1,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,714 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,713.76 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $938.66 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $781.65 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Abbvie INC. | $625.01 | 2021-2025 | |
| Amgen INC. | $503.66 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $460.20 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $414.99 | 2021-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $347.77 | 2021-2025 | |
| Lilly USA, LLC | $200.11 | 2022-2025 | Taltz, Ebglyss, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.34 | 2023-2025 | Spevigo |
| Genentech USA, INC. | $182.53 | 2021-2023 | Erivedge |
| Almirall LLC | $150.01 | 2021-2025 | Seysara, Klisyri |
| E.R. Squibb & Sons, L.L.C. | $122.38 | 2023-2025 | Sotyktu |
| Incyte Corporation | $66.89 | 2022-2023 | Opzelura |
| Organogenesis INC. | $61.82 | 2022-2023 | Puraply |
| Kerecis Limited | $60.47 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $59.45 | 2025 | Bimzelx |
| Dermavant Sciences, INC. | $43.61 | 2022-2023 | Vtama |
| Pfizer INC. | $37.34 | 2022 | |
| Arcutis Biotherapeutics, INC. | $34.52 | 2023-2024 | Zoryve |
| Botanix Sb INC | $21.95 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.06 | 2021 | |
| Organon LLC | $20.71 | 2025 | Vtama |
| Paratek Pharmaceuticals, INC. | $19.21 | 2024 | Nuzyra |
| Galderma Laboratories, L.P. | $15.62 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nichol Raulerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.